Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Kirrberger Straße Building 46, 66421, Homburg, Germany.
Anal Bioanal Chem. 2021 Sep;413(22):5551-5559. doi: 10.1007/s00216-021-03311-w. Epub 2021 Apr 1.
The still increasing number of drugs of abuse, particularly the so-called new psychoactive substances (NPS), poses an analytical challenge for clinical and forensic toxicologists but also for doping control. NPS usually belong to various classes such as synthetic cannabinoids, phenethylamines, opioids, or benzodiazepines. Like other xenobiotics, NPS undergo absorption, distribution, metabolism, and excretion processes after consumption, but only very limited data concerning their toxicokinetics and safety properties is available once they appear on the market. The inclusion of metabolites in mass spectral libraries is often crucial for the detection of NPS especially in urine screening approaches. Authentic human samples may represent the gold standard for identification of metabolites but are often not available and clinical studies cannot be performed due to ethical concerns. However, numerous alternative in vitro and in vivo models are available. This trends article will give an overview on selected models, discuss current studies, and highlight recent developments.
滥用药物的数量仍在不断增加,特别是所谓的新型精神活性物质(NPS),这给临床和法医毒理学家以及兴奋剂检测带来了分析上的挑战。NPS 通常属于各种类别,如合成大麻素、苯乙胺、阿片类药物或苯二氮䓬类药物。与其他外源性物质一样,NPS 在消费后会经历吸收、分布、代谢和排泄过程,但一旦它们出现在市场上,关于其毒代动力学和安全特性的数据非常有限。将代谢物纳入质谱谱库对于检测 NPS 通常至关重要,特别是在尿液筛查方法中。真实的人体样本可能是鉴定代谢物的金标准,但由于伦理问题,通常无法获得,也无法进行临床研究。然而,有许多替代的体外和体内模型可供选择。本文将概述选定的模型,讨论当前的研究,并强调最新的进展。